Table 2 Univariate analyses of the interval and other covariates based on Cox regression model
Factors | OS | DFS | DMFS | LRFS | ||||
|---|---|---|---|---|---|---|---|---|
HR (95% CI) | P* | HR (95% CI) | P* | HR (95% CI) | P* | HR (95% CI) | P* | |
Interval between IC and RT (> 30 vs. ≤ 30 days) | 2.43 (1.49–3.95) | < 0.001 | 1.90 (1.22–2.95) | 0.005 | 2.67 (1.57–4.53) | < 0.001 | 1.57 (0.78–3.16) | 0.208 |
Age (continuous) | 1.02 (1.01–1.04) | 0.010 | 1.02 (1.00–1.03) | 0.040 | 1.00 (0.98–1.02) | 0.899 | 1.01 (0.99–1.03) | 0.240 |
Sex (Female vs. Male) | 0.85 (0.54–1.34) | 0.487 | 1.00 (0.69–1.43) | 0.985 | 1.04 (0.65–1.67) | 0.866 | 1.24 (0.74–2.07) | 0.425 |
T category (T3–4 vs. T1–2) | 1.45 (0.87–2.41) | 0.149 | 1.28 (0.86–1.92) | 0.228 | 1.15 (0.68–1.92) | 0.608 | 1.54 (0.81–2.92) | 0.192 |
N category (N2–3 vs. N0–1) | 2.22 (1.52–3.24) | < 0.001 | 1.66 (1.21–2.28) | 0.002 | 3.17 (2.08–4.85) | < 0.001 | 0.82 (0.49–1.38) | 0.464 |
lnDNA (continuous) | 1.06 (1.01–1.12) | 0.022 | 1.07 (1.02–1.12) | 0.004 | 1.17 (1.09–1.26) | < 0.001 | 1.04 (0.98–1.11) | 0.187 |
WHO pathology (III vs. I/II) | 0.59 (0.30–1.18) | 0.135 | 0.75 (0.41–1.39) | 0.361 | 1.25 (0.46–3.41) | 0.661 | 0.43 (0.21–0.90) | 0.025 |
CCI (≥ 1 vs. 0) | 2.03 (1.29–3.21) | 0.002 | 1.74 (1.18–2.57) | 0.005 | 1.22 (0.69–2.16) | 0.496 | 1.38 (0.74–2.58) | 0.310 |
IC cycles (> 2 vs. ≤ 2) | 1.29 (0.88–1.89) | 0.187 | 1.25 (0.91–1.71) | 0.170 | 1.39 (0.92–2.12) | 0.118 | 1.26 (0.79–2.03) | 0.336 |
Concurrent chemotherapy (Yes vs. No) | 0.97 (0.60–1.56) | 0.903 | 0.99 (0.67–1.46) | 0.946 | 1.10 (0.64–1.89) | 0.728 | 1.05 (0.58–1.92) | 0.869 |